Methotrexate potentiates anti-herpes simplex virus type 1 activity of E-5-(2-bromovinyl)-2'-deoxyuridine.
The pharmacologic of induction of low level of deoxyribonucleoside triphosphates (dNTP) is a novel approach to combined inhibition of virus replication. In accordance with this concept the alteration of antiherpes activity of E-5-(2-bromovinyl-2'-deoxyuridine (BVDU) in combination with methotrexate (MTX), an inhibitor which lowers the intracellular pool of thymidine triphosphate (dTTP) was studied. MTX applied alone at non-toxic concentrations had a moderate effect on herpes simplex virus type 1 (HSV-1) replication in human embryonic skin-muscle fibroblasts. The combination of BVDU and MTX acts synergistically, as measured by virus yield assay in the above mentioned system. The potentiating effect of MTX on the anti-HSV-1 activity of BVDU was reversed by thymidine (dThd).
Pancheva
S N
SN
Institute of Microbiology, Bulgarian Academy of Sciences, Sofia.
D000998:Antiviral Agents / Q000494:pharmacology*; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002460:Cell Line; D004357:Drug Synergism; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology*
D000998:Antiviral Agents; C020235:brivudine; D001973:Bromodeoxyuridine; D008727:Methotrexate